Payment overview · 2025
General Payments
$4,229.73
199 reported records · 31 companies
Healthcare provider profile · identity verified
William Charles Ware, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ASTON, PA · NPI 1497716849
Verified facts
What the public records show
CMS Open Payments records show William Charles Ware, M.D. received $4,229.73 in general payments during 2025 across 199 reported records.
Novo Nordisk Inc accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $482.45 | 11.4% | 23 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $413.55 | 9.8% | 16 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $405.79 | 9.6% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $379.87 | 9.0% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $294.46 | 7.0% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $229.48 | 5.4% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $179.86 | 4.2% | 4 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $171.32 | 4.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $162.94 | 3.9% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $147.63 | 3.5% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $142.35 | 3.4% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $129.80 | 3.1% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $110.95 | 2.6% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $109.45 | 2.6% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $95.62 | 2.3% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $95.59 | 2.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $87.41 | 2.1% | 5 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.28 | 1.7% | 4 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $70.32 | 1.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.37 | 1.4% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $56.22 | 1.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $53.34 | 1.3% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $51.80 | 1.2% | 3 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.66 | 1.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $39.49 | 0.9% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $38.25 | 0.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $25.33 | 0.6% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.25 | 0.5% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $20.30 | 0.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $19.53 | 0.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $19.07 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,229.73 | 199 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $264.85 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $254.81 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $249.03 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $248.81 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $228.23 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $217.60 | 15 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $217.60 | 15 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $198.24 | 5 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $171.32 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $167.90 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $162.94 | 7 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $151.64 | 10 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $151.64 | 10 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $151.64 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $148.64 | 7 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $147.63 | 10 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $146.66 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $141.76 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $122.02 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $121.04 | 10 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $110.95 | 5 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $109.45 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $95.62 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $95.59 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.69 | 5 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $73.28 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $70.32 | 4 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $70.32 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $70.07 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $59.37 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.13 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $56.22 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $53.34 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $51.80 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $45.43 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $39.49 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.33 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $19.63 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $4.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 33 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 71 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 52 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
71 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
63 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 658 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 170 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 410 | 107 |
| Lisinopril | Lisinopril | 352 | 107 |
| Alprazolam | Alprazolam | 281 | 55 |
| Omeprazole | Omeprazole | 263 | 71 |
| Metformin Hcl | Metformin Hcl | 239 | 68 |
| Gabapentin | Gabapentin | 237 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 64 |
| Losartan Potassium | Losartan Potassium | 211 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 31 |
| Furosemide | Furosemide | 135 | 52 |
| Eliquis | Apixaban | 134 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 126 | 18 |
| Metformin Hcl Er | Metformin Hcl | 119 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 38 |
| Montelukast Sodium | Montelukast Sodium | 115 | 28 |
| Lorazepam | Lorazepam | 106 | 18 |
| Potassium Chloride | Potassium Chloride | 106 | 34 |
| Valsartan | Valsartan | 106 | 27 |
| Simvastatin | Simvastatin | 105 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 97 | 25 |
| Donepezil Hcl | Donepezil Hcl | 97 | 34 |
| Trazodone Hcl | Trazodone Hcl | 97 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 27 |
| Sertraline Hcl | Sertraline Hcl | 93 | 23 |
| Ezetimibe | Ezetimibe | 92 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 28 |
| Tramadol Hcl | Tramadol Hcl | 83 | 29 |
| Famotidine | Famotidine | 82 | 25 |
| Ibuprofen | Ibuprofen | 82 | 31 |
| Ramipril | Ramipril | 81 | 29 |
| Alendronate Sodium | Alendronate Sodium | 79 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 79 | 21 |
| Clonazepam | Clonazepam | 76 | 26 |
| Azithromycin | Azithromycin | 74 | 57 |
| Farxiga | Dapagliflozin Propanediol | 71 | 17 |
| Meloxicam | Meloxicam | 71 | 18 |
| Prednisone | Prednisone | 69 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 15 |
| Glimepiride | Glimepiride | 67 | 19 |
| Mounjaro | Tirzepatide | 67 | 13 |
| Carvedilol | Carvedilol | 63 | 15 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 55 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Oxcarbazepine | Oxcarbazepine | 61 | suppressed |
| Atenolol | Atenolol | 59 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 55 | 50 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Bupropion Xl | Bupropion Hcl | 53 | 15 |
| Glipizide Er | Glipizide | 53 | 11 |
| Irbesartan | Irbesartan | 53 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 15 |
| Azelastine Hcl | Azelastine Hcl | 52 | 16 |
| Ozempic | Semaglutide | 52 | 16 |
| Synthroid | Levothyroxine Sodium | 52 | 14 |
| Allopurinol | Allopurinol | 51 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 50 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 12 |
| Jardiance | Empagliflozin | 45 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Fenofibrate | Fenofibrate | 44 | 12 |
| Finasteride | Finasteride | 40 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | 17 |
| Benazepril Hcl | Benazepril Hcl | 39 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Nifedipine Er | Nifedipine | 39 | 11 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 14 |
| Amoxicillin | Amoxicillin | 33 | 27 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 13 |
| Meclizine Hcl | Meclizine Hcl | 31 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 26 |
| Doxepin Hcl | Doxepin Hcl | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | 11 |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Oxycontin | Oxycodone Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,229.73 · 199 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, BRIXADI, Belbuca, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Fluad, Flucelvax, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LOREEV XR, MAVYRET, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WAKIX, Wegovy, XIFAXAN, XTAMPZA, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error